Improved blood sugar control may also benefit people with conditions like polycystic ovary syndrome (PCOS), which is associated with insulin resistance
Ozempic and Wegovy were among 15 drugs the Biden administration added to the list that the CMS will negotiate prices for by 2027
doi: 10.1002/phar.2797 [PubMed] 37259844 Johannessen Landmark C, Eyal S, Burns ML, Franco V, Johannessen SI
If you experience severe abdominal pain, seek urgent medical attention
Recent federal and state-level pushes, including the Treat and Reduce Obesity Act, aim to expand insurance coverage for FDA-approved weight loss medications and counseling services
%20at%20the%200.25%E2%80%AFmg%20weekly%20starter%20dose%2C%20and%20is%20this%20regimen%20safe%3F)
Physicians should avoid prescribing to: Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) Individuals with severe gastrointestinal disorders (such as gastroparesis) Patients with a known hypersensitivity to GLP-1 or GIP receptor agonists Pregnant or breastfeeding women, unless deemed necessary by a healthcare provider Potential Side Effects Like any medication, this may cause side effects, though most are mild and transient. Common Side Effects (Usually Improve Over Time) Mild nausea (most common, usually decreases after the first few weeks) Vomiting or diarrhea in some cases, especially during dose escalation Constipation or bloating as digestion slows Mild fatigue or headaches as the body adjusts Less Common But Serious Side Effects Severe gastrointestinal distress (persistent nausea, vomiting, or diarrhea requiring discontinuation) Pancreatitis (rare) Monitor for severe abdominal pain Hypoglycemia (rare in non-diabetics) May occur if combined with other insulin-stimulating agents Allergic reactions (very rare) Swelling, rash, or difficulty breathing Physicians should titrate doses gradually to minimize side effects and improve patient tolerance
